Navigation Links
Evidence links anemia drugs with leukemic transformation in patients with primary myelofibrosis
Date:12/10/2007

ATLANTA -- Mayo Clinic researchers today reported the discovery of a link between erythropoiesis-stimulating agents (ESAs) and leukemic transformation (conversion to leukemia) of the blood disorder myelofibrosis. The results of the retrospective study, which sought to quantify the risk factors for leukemic transformation, were presented by lead author Jocelin Huang, M.D., at the American Society of Hematologys annual meeting.

We believe this to be the first large systematic evaluation of the risk factors leading to leukemic transformation in primary myelofibrosis, says Dr. Huang, hematology researcher at Mayo Clinic. And in the process, we discovered some unexpected results.

The researchers confirmed a number of clinical and laboratory variables that appeared to correlate with leukemic transformation. Independent risk factors for development of leukemia included peripheral blood blast (immature leukemia cells) levels greater than or equal to 3 percent; and a platelet count of less than 100x109/liter (L). The more surprising findings were that specific treatments also appeared to be related to leukemic transformation. Use of ESAs or danazol (a hormone with anemia-countering properties) were linked to later development of leukemia, independent of the blast or platelet levels.

Ayalew Tefferi, M.D., principal investigator of the study, and a Mayo Clinic hematologist, cautions that the current findings are based on retrospective observation and need to be validated in properly designed prospective studies. While we cannot take these findings as an absolute, at the same time, they cannot be ignored, says Dr. Tefferi. Treatment decisions regarding the use of ESAs in patients with primary myelofibrosis should carefully be evaluated.

He also points out that ESA treatment in patients with primary myelofibrosis has the potential to cause further enlargement of the spleen (a known complication of the disease).

The study evaluated the records of 311 Mayo Clinic patients, seen with primary myelofibrosis between 1976 and 2006. Of these patients, at an average follow-up of 27 months, 27 cases (9 percent) of leukemic transformation were documented.

Other factors appeared to contribute to the development of leukemia, including anemia, leukocytosis and peripheral blood monocyte count greater than or equal to 1x109/L (both are measures of elevated white blood cells), hypercatabolic symptoms (results of excess metabolism), a splenectomy and treatment with androgens (a type of hormones). However, they were not independent predictors.


'/>"/>

Contact: Elizabeth Zimmermann
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
2. No strong evidence linking amateur boxing with long-term brain injury
3. AHRQ Announces Next Phase of Its Evidence-Based Practice Center Program
4. Vanderbilt Medical Center chosen as Evidence-based Practice Center
5. Little Evidence Silicone Breast Implants Harm Health
6. Consumers Should Demand Evidence, Not Guesswork, On Meat-Cancer Links
7. U of M study: Medicare lacks tools, incentives to enforce evidence-based coverage policies
8. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
9. Scientific evidence of the significant anti-cancer effect of milk thistle
10. Defining the Value of Medicine in an Evidence-Based Healthcare Marketplace
11. UC Davis researchers find evidence of mature heart cell potential in embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices ... But this approach has proven transformative, both for people who hear voices and for ... is used around the world, but it still lags in the United States. , ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... particular advertising campaigns, to monitor the performance of sales and support staff, and ... and revenue. The software allows customers to record, transcribe, route, document, and report ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Like jewels in ... clients already know – London is home to Ontario’s leading day spa and one ... visionary Fayez Tamba began with a unique concept to combine spa services with ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Spectrum Aquatics has ... new lift has been designed and built with the user in mind. , “Over ... consultants have informed us that an ADA 400 lbs lift is a necessary requirement ...
(Date:5/31/2016)... ... ... TeaZa® Energy, LLC announces the launch of a new limited edition ... The new flavor—Tropical TeaZa? Energy—will be available to customers exclusively online starting today, ... is best described as a juicy, taste bud takeover. A mouthwatering wave of ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... , May 31, 2016 ... and Annotate Content From Elsevier,s ScienceDirect Database ... scientific, technical and medical information products and services, ... Berlin -based scientific collaboration platform PaperHive to enable ... over 12 million articles on ScienceDirect , ...
(Date:5/31/2016)... ZIONA, Israel , May ... regenerative medicine company utilizing its proprietary plant-based rhCollagen technology ... received authorization from the Chief Scientist of ... 50% of its NIS 12 million development project for ... measurably higher than last year,s authorized grant, which totaled ...
(Date:5/31/2016)... -- 194 Mitgliedsstaaten verpflichten sich ... viraler Hepatitis    Am 28. Mai ... Hepatitis bis 2030 zu eliminieren. Bei der ... sich die Staaten einstimmig dafür entschieden, die erste ... Strategy) zu verabschieden, was das bisher weltweit größte ...
Breaking Medicine Technology: